Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash from Investing Activities: 2022-2023

Historic Cash from Investing Activities for Therapeutics (LENZ) over the last 2 years, with Dec 2023 value amounting to $15.2 million.

  • Therapeutics' Cash from Investing Activities rose 12.19% to $15.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$29.6 million, marking a year-over-year increase of 87.75%. This contributed to the annual value of -$154.5 million for FY2024, which is 421.52% down from last year.
  • As of Q4 2023, Therapeutics' Cash from Investing Activities stood at $15.2 million, which was up 184.70% from -$17.9 million recorded in Q3 2023.
  • Over the past 5 years, Therapeutics' Cash from Investing Activities peaked at $15.2 million during Q4 2023, and registered a low of -$170.7 million during Q1 2022.
  • Moreover, its 2-year median value for Cash from Investing Activities was -$9.0 million (2023), whereas its average is -$33.9 million.
  • Within the past 5 years, the most significant YoY rise in Therapeutics' Cash from Investing Activities was 100.00% (2023), while the steepest drop was 612.39% (2023).
  • Over the past 2 years, Therapeutics' Cash from Investing Activities (Quarterly) stood at $13.5 million in 2022, then increased by 12.19% to $15.2 million in 2023.
  • Its Cash from Investing Activities stands at $15.2 million for Q4 2023, versus -$17.9 million for Q3 2023 and -$26.9 million for Q2 2023.